Determinação de lumefantrina em plasma humano empregando extração em fase sólida molecularmente impressa e cromatografia a líquido de alta eficiência

• Ano de defesa: 2017
• Autor(a) principal: Pedro Henrique Reis da Silva
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Minas Gerais; UFMG
• Palavras-chave em Português: Doehlert; Lumefantrina; Extração em Fase Sólida; Planejamento Experimental; Polímero de Impressão Molecular; Malária; Box Behnken; Malária Tratamento; Polímeros; Planejamento experimental
• Link de acesso: http://hdl.handle.net/1843/BUOS-BB3KA6

Malaria is an infectious disease caused by protozoan of genus Plasmodium. Although declining, malaria remains a public health issue in Brazil. Treatment of malaria is carried out using association of different drugs aiming to reach the parasite in key points of its biological cycle. The first-choice treatment for infections caused by P. falciparum consists in artemether and lumefantrine in a fixed dose combination. One of the challenges for malaria eradication is the resistance of parasites to antimalarials. Therefore, quantification of drugs in biological fluids is imperative for therapeutic drug monitoring, since subtherapeutic doses are related to drug resistance and therapeutic failure. Employing suitable bioanalytical methods is then crucial to obtain reliable results. However, since biological matrices are complex, a sample preparation step is required for removal of interferences and preconcentration of analytes. Molecularly imprinted polymers (MIPs) has emerged as a highly selective alternative among available sample preparation materials, being also relatively easy, inexpensive and simple to obtain. Therefore, it was aimed with this study synthesizing a MIP for lumefantrine using a Box-Benhken design. This MIP was synthesized using 2-vinylpyridine, ethylene glycol dimethacrylate and toluene and was then characterized. Distribution coefficient (977.83 g/g), imprinting factor (2.44) and selectivity factor (1.44) were determined. This polymer was used for extraction of lumefantrine from human plasma samples by means of molecularly imprinted solid-phase extraction (MISPE). A bioanalytical method for determination of lumefantrine in plasma was developed and validated employing a Kinetex C18 (100 x 4.6 mm, 2,6 m) column, a mixture of methanol, acetonitrile and 0.14% aqueous solution of trifluoroacetic acid (50:33:17) as mobile phase, at a flow-rate of 0.7 mL/min, at 35 °C, detection at 305 nm and halofantrine as internal standard. The method fulfilled validation parameters of carryover, matrix effect and stability, showing to be selective, accurate, precise and linear in the range of 50-10000 ng/mL. The limit of quantification and recoveries were found to be 50 ng/mL and 83.7-85.4%, respectively. The developed and validated method was suitable for determination of lumefantrine in human plasma.